PROTECT Study in Children and Adolescents with Newly Diagnosed Type 1 Diabetes (T1D)
The PROTECT Study will assess how well an investigational medicine, called teplizumab, works in children and adolescents recently diagnosed with Type 1 diabetes (T1D). ‘Investigational’ means that the medicine has not been approved for the treatment of T1D and is still being evaluated in clinical studies such as this one. The investigational medicine will be compared with a placebo – a substance that looks like teplizumab but contains no real treatment. The PROTECT Study will also assess whether there are any side effects from taking the investigational medicine.
This research study is led by Dr. Ksenia Tonyushkina.
Contact: Victoria Cobb, 413-794-1466
February 06, 2020
Baystate Children’s Specialty Center, 50 Wason Avenue, Springfield, MA
- Participant has recently received a diagnosis of type 1 diabetes
- Participant is between the ages of 8 and 17
Approximately 84 weeks